

PRODUCT PORTFOLIO



Excellence through EU GMP-Approved facility

Trusted manufacturer of CEP-grade Metformin HCl, Gliclazide with global regulatory compliance for API, DC Granules and Pellets Facility.



End-to-End Solutions

From API to DC Granules to Finished Formulations -complete vertical integration for superior quality control.



Quality You Can Trust

Delivering consistent, high quality API, DC Granules and Pellets that exceed industry standards.



Robust Product Development

We specialize in developing pharmaceutically equivalent and bioequivalent products, backed by eCTD-compliant dossiers.



Specialized CDMO Approach

A distinctive CDMO model offering flexible, customized solutions tailored to individual client needs.



TGA



Active Pharmaceutical Ingredients

Product	Therapeutic Category	Regulatory Status	
		CEP	DMF For RoW

For Regulated and Semi Regulated Market

Metformin HCl USP/EP/BP/JP/IP	Anti-Diabetics	✓	✓
Gliclazide EP/BP/IP	Anti-Diabetics	✓	✓
Folic Acid USP/EP/BP/IP	Vitamin	CEP Filed	✓
Dapagliflozin USP/EP/IP/IH	Anti-Diabetics	CEP Filed	
Rebamipide IH/JP	Anti-Ulcer	JDMF Filed	
Alogliptin Benzoate IH	Anti-Diabetics		✓

For Regulated and Semi Regulated Market

Imeglimin HCl IH	Anti-Diabetics		Pipeline (Q3 2026)
Empagliflozin IH	Anti-Diabetics		Pipeline (Q4 2026)
Tamsulosin USP/EP/BP	Alpha-Blockers		Pipeline (Q3 2026)

For Non Regulated Market

Ambroxol HCl EP/BP/IP	Mucolytics		✓
Sitagliptin Phosphate USP/EP/BP/IP	Anti-Diabetics		Teckpack Available

Semi Finished Formulation (DC Granules)

Product	Therapeutic Category	Regulatory Status
---------	----------------------	-------------------

Metformin HCl DC - IR 83.33%, 86.6%, 90%, 93.6%, & 95% w/w	Anti-Diabetics	DMF Available
Metformin HCl DC - XR 64.44%, 69.44%, 73.5% & 77.52% w/w	Anti-Diabetics	DMF Available
Methocarbamol DC 90% w/w	Pain Medication	DMF Available
Gliclazide DC Modified Release 18.75%, 30% w/w	Anti-Diabetics	DMF under Compilation
Alpha Lipoic Acid Granules 80% w/w	Antioxidant	R&D Developed
Guaifenesin DC 95% w/w	Expectorant	R&D Developed
Paracetamol DC 90% w/w	Anti-Pyretics	R&D Developed

Pre Finished Formulation Intermediates (PFIs)

Product	Therapeutic Category	Status
Orlistat Pellets 50% w/w	Anti-Obesity	DMF Available
Esomeprazole EC Pellets/MUPS* 8.5%, 22%, 22.5% w/w	Proton Pump Inhibitor	DMF Available
Fenofibrate Pellets 66.234% w/w	Lipid Modifying agent	DMF under Compilation
Topiramate Sprinkle Pellets 22.32% w/w	Anti-Convulsant	DMF under Compilation
Metoprolol Succinate ER Pellets** 62% w/w	Anti-Hypertensive	DMF under Compilation
Itraconazole Pellets 22% / 44% w/w	Anti-Fungal	DMF under Compilation
Omeprazole EC Pellets 7.5% 8.5%, 12.5% 22.5% w/w	Proton Pump Inhibitor	DMF under Compilation
Lansoprazole EC Pellets/MUPS 8.5%, 12.5% w/w	Proton Pump Inhibitor	DMF under Compilation
Fenofibric Acid Pellets 29% w/w	Lipid Modifying agent	R&D Developed
Dexlansoprazole DDR Pellets 17%, 20%, 22.5%, 23% w/w	Proton Pump Inhibitor	R&D Developed
Pantoprazole EC Pellets 15% w/w	Proton Pump Inhibitor	R&D Developed
Domperidone Pellets 20%, 22% w/w	Anti-Emetics	R&D Developed
Diclofenac Pellets 30%, 33.5% w/w	Anti-Inflammatory	R&D Developed
Tamsulosin HCl SR Pellets 0.12%, 0.125%, 0.16%, 0.2% w/w	Alpha-Blockers	DMF under Compilation
Tamsulosin HCl SR Pellets + Dutasteride IR Pellets (0.4 mg) (0.5 mg)	Alpha-Blockers	DMF under Compilation
Duloxetine Pellets 17%, 17.65%, 20% w/w	Anti-Depressant	R&D Developed
Venlafaxine Pellets 32%, 33% w/w	Anti-Depressant	R&D Developed
Mebeverine Pellets 76%, 80% w/w	Anti-Cholinergic	R&D Developed
Mesalamine SR Pellets 70%, 90%, 96.38% w/w	Anti-Inflammatory	R&D Developed
Aprepitant Pellets 40% w/w	Anti-Emetics	R&D Developed
Clopidogrel Pellets 50% w/w	Anti-Platelet	R&D Developed

*CDMO product, exclusively manufacturing for our customer

**CDMO product, exclusive for Korea market, other markets are open

Finished Formulation

Product	RLD	Formulation/Pack	Status
Products Ready With Dossier			
Metformin XR 500mg, 750mg, 1000mg	Glucophage SR	Tablets/Blisters	MA received in Germany, Bulgaria, Poland and UK
Dapagliflozin 5mg, 10mg	Forxiga	Tablets	Dossier Available
Fosfomycin Tromethamine 3gm	Monurol	Granules for Oral Solution/Pouch	Product filed in CANADA
Loratadine 5mg	Claratyne	Chewable Tab	Product Filed in Australia
Paracetamol 500mg	Panadol	Effervescent Tab	Product filed in Australia and UK
Sevelamer Carbonate 2.4 gm, 0.8 gm	Renvela	Powder for Oral Suspension	Product filed in CANADA

Products Ready, Dossier Under Compilation			
Topiramate 15mg, 25mg, 50mg	Topamax	Sprinkle Capsule	Dossier ready for UK submission, For Europe in Q1 2026
Dapagliflozin, Metformin IR 5mg,850mg; 5mg,1gm	Xigduo	Tablets	Dossier by Q1 2026
Sitagliptin, Metformin XR 50mg,500mg; 50mg,1gm; 100mg,1gm	Janumet XR	Tablets	Dossier by Q3 2026
Dapagliflozin, Metformin XR 2.5mg,1gm; 5mg,500mg; 5mg,1gm; 10mg,500mg; 10mg,1gm	Xigduo XR	Tablets	Dossier by Q4 2026
Gliclazide MR 30 mg, 60 mg	Diamicron MR	Tablets	Dossier by Q3 2026

Products Under Development			
Sitagliptin 25mg, 50mg, 100mg	Januvia	Tablets	Development completed, Ready for execution
Sitagliptin, Metformin IR 50mg,500mg; 50mg,850mg; 50mg,1gm	Janumet	Tablets	Development completed, Ready for execution
Empagliflozin 10mg, 25mg	Jardiance	Tablets	Development Initiated, Dossier by Q3 2026
Empagliflozin, Metformin: 5mg,500mg ; 5mg,1gm ; 12.5mg,500mg ; 12.5mg,1gm.	Synjardy	Tablets	Development Initiated, Dossier by Q4 2026
Empagliflozin, Metformin XR 5mg,1gm ; 10mg,1gm ; 12.5mg,1gm.	Synjardy XR	Tablets	Development Initiated, Dossier by Q4 2026

Corporate Address
7110, 7120, Marvel Fuego,
Magarpatta Road, Opp. Seasons Mall,
Hadapsar, Pune – 411028 ,
Maharashtra, India

Contact Details
Phone No.: +91 (20) 26890771

Factory Address
D 30, Kurkumbh, MIDC, Tal Daund,
Dist Pune 413802, Maharashtra
India

Email
marktg@sohanhealthcare.com

